Inactive Instrument

Analyst Reco. Silence Therapeutics plc London S.E.

Equities

Chardan Boosts Price Target on Silence Therapeutics to $42 From $26 on Positive Data From Zerlasiran Study, Keeps Buy Rating	Mar. 14	MT
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating	Mar. 14	MT
BMO Capital Starts Silence Therapeutics With Outperform Rating, $67 Price Target	Jan. 31	MT
HC Wainwright Adjusts Silence Therapeutics Price Target to $75 From $80, Maintains Buy Rating	Nov. 17	MT
Chardan Adjusts Price Target on Silence Therapeutics to $26 From $29, Maintains Buy Rating	23-03-16	MT

No results for this search